News

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation TOKYO, Dec. 3, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the 61 st American Society of Hematology (ASH) Annual Meeting, taking place Dec. 7-10 in...

- Companies to Initiate Phase 3 Trial to Support Global Registrations - BOTHELL, Wash., and TOKYO, December 2, 2019 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the...

- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company - Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufacturing expansion for the combined entity - Acquisition price of US$60 per share in cash, representing a total...